Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 559-572
Open Access | Times Cited: 236

Showing 1-25 of 236 citing articles:

The pathogenesis of Parkinson's disease
Huw R. Morris, Maria Grazia Spillantini, Carolyn M. Sue, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 293-304
Open Access | Times Cited: 267
Trial of Lixisenatide in Early Parkinson’s Disease
Wassilios G. Meissner, Philippe Rémy, Caroline Giordana, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1176-1185
Closed Access | Times Cited: 117
Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy
Xiaoyan Gao, Tuo Yang, Ying Gu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 73
Medical, surgical, and physical treatments for Parkinson's disease
Thomas Foltynie, Verónica Bruno, Susan H. Fox, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 305-324
Open Access | Times Cited: 72
Disease modification in inflammatory skin disorders: opportunities and challenges
Thomas Bieber
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 662-680
Closed Access | Times Cited: 43
A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects
Mauricio Muleiro Álvarez, Gabriela Cano-Herrera, María Fernanda Osorio Martínez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7183-7183
Open Access | Times Cited: 15
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
The Lancet (2025)
Open Access | Times Cited: 2
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
Philipp Mahlknecht, Thomas Foltynie, Patricia Limousin, et al.
Movement Disorders (2022) Vol. 37, Iss. 8, pp. 1581-1592
Open Access | Times Cited: 57
Prodromal Parkinson's disease: hype or hope for disease-modification trials?
Philipp Mahlknecht, Kathrin Marini, Mario Werkmann, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 47
Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease
Shinichi Takahashi, Kyoko Mashima
Antioxidants (2022) Vol. 11, Iss. 1, pp. 170-170
Open Access | Times Cited: 43
Mitochondrial Sirtuins in Parkinson’s Disease
Ling He, Jihong Wang, Yazhi Yang, et al.
Neurochemical Research (2022) Vol. 47, Iss. 6, pp. 1491-1502
Closed Access | Times Cited: 40
Neuroprotective effects of morroniside from Cornus officinalis sieb. Et zucc against Parkinson’s disease via inhibiting oxidative stress and ferroptosis
Li Mao, Junli Zhang, Lianyan Jiang, et al.
BMC Complementary Medicine and Therapies (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 31
Prosaposin maintains lipid homeostasis in dopamine neurons and counteracts experimental parkinsonism in rodents
Yachao He, Ibrahim Kaya, Mohammadreza Shariatgorji, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 25
Engineered Selenium/Human Serum Albumin Nanoparticles for Efficient Targeted Treatment of Parkinson’s Disease via Oral Gavage
Kai Xu, Peng Huang, Yixuan Wu, et al.
ACS Nano (2023) Vol. 17, Iss. 20, pp. 19961-19980
Open Access | Times Cited: 25
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases
Elizabeth M. Rhea, Alice Babin, P. C. Thomas, et al.
Tissue Barriers (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 25
Two-year clinical progression in focal and diffuse subtypes of Parkinson’s disease
Martin E. Johansson, Nina M. van Lier, Roy P. C. Kessels, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 22
DNA Damage-Mediated Neurotoxicity in Parkinson’s Disease
Zhong‐Xuan Wang, Yaolin Li, Jiali Pu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6313-6313
Open Access | Times Cited: 22
The Role of IL-6 in Neurodegenerative Disorders
Chen Shan, Chao Zhang, Chuanbao Zhang
Neurochemical Research (2024) Vol. 49, Iss. 4, pp. 834-846
Closed Access | Times Cited: 13
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Angeliki Zarkali, George E. Thomas, Henrik Zetterberg, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Targeting modulation of intestinal flora through oral route by an antimicrobial nucleic acid-loaded exosome-like nanovesicles to improve Parkinson’s disease
Weitong Cui, Zhiyong Guo, Xingyu Chen, et al.
Science Bulletin (2024)
Closed Access | Times Cited: 11
Early-stage idiopathic Parkinson’s disease is associated with reduced circular RNA expression
B Whittle, Osagie Izuogu, Hannah Lowes, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson’s disease
Akshay Bandiwadekar, Jobin Jose, Gopika Gopan, et al.
Drug Delivery and Translational Research (2024)
Closed Access | Times Cited: 9
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)
Andreas Wolff, Helen Bidner, Yvonne Remane, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 8
Salivary Biomarkers for Parkinson’s Disease: A Systematic Review with Meta-Analysis
Kacper Nijakowski, Wojciech Owecki, Jakub Jankowski, et al.
Cells (2024) Vol. 13, Iss. 4, pp. 340-340
Open Access | Times Cited: 8
Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson’s disease
Shenzhong Jiang, Han Wang, Chengxian Yang, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024) Vol. 95, Iss. 12, pp. 1102-1111
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top